Drug Database
EP

epoetin alfa (Epiao 36000IU)

✓ Approved

3SBio · EPOR · 重组蛋白

什么是 epoetin alfa?

epoetin alfa 是一种重组蛋白,由3SBio研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Epiao 36000IU
公司3SBio
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

epoetin alfa 作用于 1 个分子靶点:

EPORerythropoietin receptor (EPO-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

epoetin alfa 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedJournal of hematology2026-11-17

Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared to Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1).

AlAli Fatima F, Alahmdi Ahmed A, Nasiri Abdulrahman A, Rasheed Walid W et al.

Acute myeloid leukemia (AML) with t(8;21) is generally classified as favorable-risk AML, with high-dose cytarabine consolidation considered standard post-remission therapy (PRT). However, relapse rates remain substantial in some populations, raising uncertainty about whether transplantation in first complete remission may benefit selected patients. We performed a retrospective analysis of 59 patients with AML t(8;21) treated entirely at a single tertiary institution. Patients received standard induction chemotherapy followed by PRT with high-dose cytarabine chemotherapy, autologous hematopoietic cell transplantation, or allogeneic hematopoietic cell transplantation. Survival outcomes, relapse incidence, prognostic factors, non-relapse mortality, and healthcare resource utilization were analyzed. The median age was 23 years, and 93% achieved complete remission after induction therapy. The 10-year event-free survival and overall survival for the entire cohort were 47% and 50%, respectively. A white blood cell count < 20 × 109/L and diagnosis after 2005 were independently associated with improved overall survival. Among 49 patients receiving adequate PRT in first remission, relapse was significantly higher with high-dose cytarabine alone compared with transplantation: 5-year cumulative incidence of relapse was 71.1% versus 31.6%, respectively. Five-year overall survival was 55.9% with high-dose cytarabine, 77.5% with autologous transplantation, and 64.6% with allogeneic transplantation. Autologous transplantation was associated with lower first-year cost and reduced bed utilization. In this cohort of predominantly young Middle Eastern patients with AML t(8;21), outcomes with high-dose cytarabine consolidation alone were modest, with an unexpectedly high relapse rate. Transplantation in first remission, particularly autologous transplantation, appeared feasible, safe, cost-effective, and associated with lower relapse risk. Prospective studies incorporating molecular risk stratification, minimal residual disease monitoring, gemtuzumab ozogamicin, quality-of-life assessment, and cost-effectiveness analyses are warranted.

PMID 43042415
阅读全文 →
PubMedEJNMMI physics2026-11-17

Pretherapeutic quantitative I-131 SPECT/CT for blood and tumour dosimetry in thyroid cancer patients with bone metastases: a pilot feasibility study.

Kwon Kyounghyoun K, Oh Dongkyu D, Kim Ji Hye JH, Yoo Jihyung J et al.

I-131 radioactive iodine (RAI) is widely used in thyroid cancer patients with bone metastases (BM). While blood-based dosimetry has been standard for predicting marrow toxicity, tumour dosimetry remains an unmet need. We evaluated the feasibility of pretherapeutic quantitative I-131 SPECT/CT for patient-tailored dosimetry in poorly differentiated thyroid carcinoma (PDTC) patients with BM. Five PDTC patients (18 BM lesions) underwent serial pre-therapeutic I-131 SPECT/CT (111 MBq, eight time points up to 120 h) with concurrent blood sampling. I-131 concentrations (MBq/g) were quantified using quantitative SPECT/CT technology and validated against gamma counting. Absorbed dose rates (Gy/h) for blood and tumours were estimated using Monte Carlo simulations (customized Geant4, cross-validated by TOPAS). Tumour absorbed doses were calculated via trapezoidal integration, and clinical outcomes were assessed after subsequent high-dose RAI therapy. Blood I-131 concentrations measured by SPECT/CT showed excellent agreement with gamma counting (p < 0.001). Blood absorbed doses per administered activity were comparable between SPECT/CT and conventional methods (p = 0.6250). Tumour I-131 concentration strongly correlated with absorbed dose rate, resulting in a regression equation [tumour absorbed dose rate (Gy/h) = 0.1256 × tumour RAI concentration (MBq/g) (R2 = 0.9918, p < 0.0001)]. Reducing imaging time points from 8 to 4 maintained the accuracy of absorbed dose estimation. Although exploratory, tumours with expected absorbed doses > 50 Gy after high-dose RAI showed no progression, whereas lower-dose lesions progressed more frequently (87.5%, p = 0.0161). In this pilot study, quantitative I-131 SPECT/CT demonstrated the reliability of pretherapeutic blood and tumour dosimetry in PDTC patients with BM. Although preliminary, these findings support its potential as a practical tool for personalized RAI therapy planning in thyroid cancer. Larger, prospective studies are warranted to validate clinical dose-response thresholds.

PMID 43040069
阅读全文 →
PubMedMedical physics2026-11-17

A condensed matter inspired framework for the FLASH effect in radiotherapy.

Shvydka Diana D, Karpov Victor V, Gupta Nilendu N

The FLASH radiation treatment utilizes ultra-high dose rates (UHDR) with short exposure times, while exhibiting a unique feature of reduced damage to healthy tissues (sparing effect). FLASH physics remains unknown. To develop a quantitative bio-physical model of FLASH radiation treatment. We explore a two-phase system of cancer inclusions embedded in a healthy host. The important morphological difference between the phases is that the cancer phase is structurally disordered, while the healthy host material is more organized. Correspondingly, the recombination times for radiation generated charge carriers are much shorter in the cancer phase than in the normal tissue host phase. In the host material, the nonequilibrium charge density under UHDR can be high enough to form electron-hole liquid suppressing generation of active radicals; hence, sparing effect. A disordered tumor phase renders channels producing radicals capable of cells destruction. The FLASH thresholds for dose and dose rates are predicted. The proposed two-phase model provides quantitative description of FLASH radiation treatment.

PMID 43040609
阅读全文 →
PubMedDrug design, development and therapy2026-11-17

Optimal Dose of Ciprofol for Anesthesia Induction in Older Hypertensive Patients with Elevated Baseline Systolic Blood Pressure: A Bayesian Phase 1/2 Trial.

Fang Jiajia J, Gao Yang Y, Wang Yi Y, Wang Jiang J et al.

To identify the optimal ciprofol induction dose for older hypertensive patients with elevated baseline invasive systolic blood pressure (SBP ≥ 140 mmHg) using a Bayesian adaptive design. This single-center, seamless phase 1/2 trial enrolled 51 hypertensive patients aged 65-80 years with baseline invasive SBP ≥ 140 mmHg undergoing elective non-cardiac procedures. General anesthesia was induced with ciprofol (0.20-0.40 mg/kg), sufentanil (0.4 µg/kg), and rocuronium (1.0 mg/kg). Phase 1 used the Bayesian Optimal Interval (BOIN) design to determine the maximum tolerated dose (MTD). Dose-limiting toxicity (DLT) was defined as post-induction hypotension (PIH; mean arterial pressure [MAP] < 65 mmHg from induction to 3 minutes post-intubation). The target DLT probability was set at 45% to accommodate the high baseline hypotension risk in this cohort. Phase 2 adopted the Bayesian Optimal Phase 2 (BOP2) design to find the optimal biological dose (OBD), evaluating both efficacy (loss of consciousness within 2 minutes without rescue dosing) and safety. Phase 1 (n = 30) identified the MTD at 0.35 mg/kg (posterior mean PIH incidence: 33%, 95% credible interval [CrI]: 11%-61%). Phase 2 (n = 21) selected 0.25 mg/kg (n = 12) as the OBD, achieving a high induction success rate (91%, 95% CrI: 71%-99%) alongside a lower PIH risk (25%, 95% CrI: 6%-52%). The peak MAP after endotracheal intubation was higher with 0.25 mg/kg than 0.35 mg/kg (126.1 ± 20.9 vs 97.8 ± 14.8 mmHg; Bonferroni-adjusted P = 0.002). Guided by the Bayesian algorithm, 0.25 mg/kg was identified as the protocol-selected OBD for older hypertensive patients with baseline invasive SBP ≥ 140 mmHg, balancing reliable anesthesia with acceptable hypotension risks. However, compared with 0.35 mg/kg, this lower dose less effectively blunts intubation-induced hypertensive surges and requires careful hemodynamic monitoring.

PMID 43042220
阅读全文 →
PubMedEJHaem2026-11-17

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia.

Bair Steven M SM, Byrd John C JC, Gutman Jonathan J, Phelps Mitchell M et al.

BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non-overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. In this multicenter, phase 1, 3+3 dose-escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28-day ibrutinib run-in (420 mg daily), then added lenalidomide with intra-patient escalation to a cohort-assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Twenty-seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow-up of 50.4 months, median progression-free survival was 69.5 months (95% CI 53.4-NE). Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. ClinicalTrials.gov identifier: NCT01886859.

PMID 43042224
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多epoetin alfa